Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunoglobulins in COVID-19 pneumonia: from the acute phase to the recovery phase.
Peraire J, García-Pardo G, Chafino S, Sánchez A, Botero-Gallego M, Olona M, Espineira S, Reverté L, Skouridou V, Peiró ÓM, Gómez-Bertomeu F, Vidal F, O' Sullivan CK, Rull A. Peraire J, et al. Eur J Med Res. 2024 Apr 6;29(1):223. doi: 10.1186/s40001-024-01824-5. Eur J Med Res. 2024. PMID: 38581072 Free PMC article.
PPARgamma Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy.
Saumoy M, Veloso S, Alonso-Villaverde C, Domingo P, Chacón MR, Miranda M, Aragonès G, Gutiérrez MM, Viladés C, Peraire J, Sirvent JJ, López-Dupla M, Aguilar C, Richart C, Vidal F; HIV Lipodystrophy Study Group. Saumoy M, et al. Among authors: peraire j. Curr HIV Res. 2009 Sep;7(5):533-40. doi: 10.2174/157016209789346219. Curr HIV Res. 2009. PMID: 19534662
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group. Mallolas J, et al. J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f. J Acquir Immune Defic Syndr. 2009. PMID: 19390327 Clinical Trial.
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team. Martínez E, et al. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5. J Acquir Immune Defic Syndr. 2009. PMID: 19398921 Clinical Trial.
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2024 Dec 23:dkae456. doi: 10.1093/jac/dkae456. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39710424
Epidemiological, clinical and mortality trends in people with HIV over 60 years in the PISCIS population-based cohort from Catalonia and Balearic Islands.
Bruguera A, Nomah DK, Moreno-Fornés S, Martinez E, Negredo E, Tiraboschi J, Navarro J, Domingo P, Fanjul F, Villoslada A, Peraire J, Jaen A, Miró JM, Casabona J, Reyes-Urueña J; and the PISCIS Study Group. Bruguera A, et al. Among authors: peraire j. AIDS. 2025 Jan 1;39(1):64-74. doi: 10.1097/QAD.0000000000004018. Epub 2024 Sep 19. AIDS. 2025. PMID: 39639721
Correction: Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients.
Trujillo-Rodriguez M, Muñoz-Muela E, Serna-Gallego A, Praena-Fernández JM, Pérez-Gómez A, Gasca-Capote C, Vitallé J, Peraire J, Palacios-Baena ZR, Cabrera JJ, Ruiz-Mateos E, Poveda E, López-Cortés LE, Rull A, Gutierrez-Valencia A, López-Cortés LF. Trujillo-Rodriguez M, et al. Among authors: peraire j. PLoS One. 2024 Nov 21;19(11):e0314574. doi: 10.1371/journal.pone.0314574. eCollection 2024. PLoS One. 2024. PMID: 39570969 Free PMC article.
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.
Izquierdo R, Suárez-García I, Gómez-García T, Marco-Sánchez C, Puente-Ferreiro J, Moreno C, Diaz A, Cabello-Clotet N, Vinuesa D, Blanco JL, Melús E, Gómez-Ayerbe C, Olalla J, Riera M, Bernardino JI, de López Bernaldo de Quirós JC, Moreno S, Jarrín I; CoRIS cohort. Izquierdo R, et al. HIV Med. 2024 Oct 25. doi: 10.1111/hiv.13726. Online ahead of print. HIV Med. 2024. PMID: 39455423
The persistence of low CD4/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function.
Garrido-Rodríguez V, Bulnes-Ramos Á, Olivas-Martínez I, Pozo-Balado MDM, Álvarez-Ríos AI, Gutiérrez F, Izquierdo R, García F, Tiraboschi JM, Vera-Méndez F, Peraire J, Rull A, Pacheco YM; CoRIS cohort. Garrido-Rodríguez V, et al. Among authors: peraire j. J Microbiol Immunol Infect. 2024 Dec;57(6):854-867. doi: 10.1016/j.jmii.2024.08.007. Epub 2024 Aug 22. J Microbiol Immunol Infect. 2024. PMID: 39209566 Free article.
160 results